Ischemic heart disease — guideline synthesis¶
TL;DR — The 2023 AHA/ACC chronic coronary disease (CCD) guideline and 2024 ESC chronic coronary syndromes (CCS) guideline agree that event prevention is systemic and revascularization in most stable patients is symptom-directed, but they organize diagnosis, LDL intensification, antianginal sequencing, and anti-inflammatory therapy differently (Virani 2023, PMID 37471501; Vrints 2024, PMID 39210710). For ACS, the 2023 ESC and 2025 ACC/AHA guidelines converge on rapid reperfusion, radial access, potent antiplatelet treatment, intensive lipid lowering, and complete revascularization in suitable multivessel disease, while timing and antithrombotic personalization remain areas of nuance (Byrne 2023, PMID 37622654; Rao 2025, PMID 40014670). The 2021 ACC/AHA/SCAI revascularization guideline distinguishes CABG from PCI by anatomy, diabetes, LV function, and surgical risk (Writing Committee Members 2022, PMID 34895950). Numerical LDL goals are more explicit and lower in ESC guidance, whereas US guidance more often uses treatment intensity and thresholds for adding non-statins. Guideline classes summarize panels' interpretation of incomplete evidence; they are not effect sizes.
Core current documents¶
| Body | Year | Region | Scope | PubMed |
|---|---|---|---|---|
| AHA/ACC/ACCP/ASPC/NLA/PCNA | 2023 | US | Chronic coronary disease | PMID 37471501 |
| ESC | 2024 | Europe | Chronic coronary syndromes | PMID 39210710 |
| ESC | 2023 | Europe | Acute coronary syndromes | PMID 37622654 |
| ACC/AHA/ACEP/NAEMSP/SCAI | 2025 | US | Acute coronary syndromes | PMID 40014670 |
| ACC/AHA/SCAI | 2021/2022 publication | US | Coronary revascularization | PMID 34895950 |
| AHA/ACC et al. | 2021 | US | Chest-pain evaluation | PMID 34709879 |
| ESC | 2021 | Europe | Cardiovascular prevention | PMID 34458905 |
| ESC/EAS | 2019 | Europe | Dyslipidaemias | PMID 31504418 |
| ESC/EAS | 2025 focused update | Europe | Dyslipidaemias update | PMID 40885687 |
The literature registry records superseded documents and watch items; this page synthesizes decisions.
Stable disease: agreement¶
Both major chronic-disease guidelines encode the trial-era distinction between symptom relief and prognosis (Virani 2023, PMID 37471501; Vrints 2024, PMID 39210710).
| Domain | Shared direction |
|---|---|
| Disease modification | High-intensity/maximally tolerated lipid lowering, antiplatelet therapy, BP/diabetes/smoking management |
| Revascularization | Symptoms despite medical therapy; selected prognostic anatomy |
| Routine testing | Avoid repeated anatomic/ischemia testing without clinical change |
| Rehabilitation | Refer after MI/revascularization and for eligible chronic disease |
| Shared decisions | Explain symptom, event, bleeding, and procedural trade-offs |
| INOCA | Recognize non-obstructive ischemic syndromes and investigate mechanism |
Neither guideline interprets COURAGE/ISCHEMIA as a ban on revascularization; both preserve left-main, complex anatomy, reduced LV function, and refractory symptoms as decision modifiers (Maron 2020, PMID 32227755).
Stable disease: important differences¶
| Issue | AHA/ACC CCD 2023 | ESC CCS 2024 |
|---|---|---|
| Taxonomy | Chronic coronary disease | Chronic coronary syndromes |
| Diagnostic framing | Integrates 2021 chest-pain guidance | Likelihood-based CCS diagnostic pathway |
| LDL escalation | Maximally tolerated statin; add non-statin at risk/LDL thresholds | Very-high-risk numerical goal plus ≥50% reduction |
| Antianginal choice | Patient-specific first-line agents | Hemodynamic/phenotype-tailored combinations |
| Colchicine | May be considered in selected patients | Incorporated with different wording/placement after accumulating evidence |
| Dual-pathway inhibition | Selected high ischemic/low bleeding risk | Similar concept with ESC risk categorization |
These differences often reflect guideline architecture and regulatory context more than contradictory trial data.
Revascularization¶
The ACC/AHA/SCAI guideline emphasizes Heart Team discussion when optimal strategy is unclear and differentiates CABG and PCI by left-main disease, multivessel complexity, diabetes, LV dysfunction, surgical risk, and ability to achieve complete revascularization (Writing Committee Members 2022, PMID 34895950).
| Phenotype | Guideline synthesis |
|---|---|
| Stable focal disease, limiting angina | PCI reasonable for symptoms after informed choice |
| Left main | CABG standard for complex anatomy; PCI alternative in selected low/intermediate complexity |
| Diabetes + multivessel CAD | CABG generally preferred when surgical candidate |
| EF ≤35% with suitable anatomy | CABG has survival evidence; PCI does not share that evidence |
| STEMI multivessel disease | Complete revascularization in stable patients, timing individualized |
The 2022 ESC/EACTS review of left-main recommendations shows how later evidence and endpoint disputes can trigger formal guideline reconsideration (Byrne 2023, PMID 37632766).
ACS convergence¶
| Decision | ESC 2023 | ACC/AHA 2025 |
|---|---|---|
| STEMI | Immediate reperfusion network | Same |
| NSTEMI | Risk-timed invasive strategy | Risk-timed invasive strategy |
| Access | Radial preferred | Radial preferred |
| DAPT | Default then individualize/de-escalate | Default then individualize |
| Multivessel STEMI | Complete revascularization in stable patients | Complete revascularization in stable patients |
| Secondary prevention | Early intensive lipids, rehab, smoking and risk-factor care | Same |
The newer US ACS guideline post-dates REDUCE-AMI, ABYSS, and contemporary DAPT-abbreviation evidence, while the 2023 ESC document necessarily relied on an earlier evidence cutoff (Byrne 2023, PMID 37622654; Rao 2025, PMID 40014670).
LDL: targets versus thresholds¶
ESC prevention/dyslipidemia guidance uses explicit LDL-C goals and percentage reduction for very-high-risk ASCVD; US guidance emphasizes high-intensity/maximally tolerated statin followed by ezetimibe and PCSK9 therapy at defined thresholds (Mach 2020, PMID 31504418; Virani 2023, PMID 37471501).
This is partly semantic: both endorse larger absolute LDL reductions for higher-risk patients. The practical disagreement is how aggressively to escalate at LDL values between the US threshold and lower ESC goal, especially when cost and injection burden are material.
Evidence grades: how to read them¶
| Element | Meaning | Common misuse |
|---|---|---|
| Class I | Recommended/indicated | Treated as proof of equal benefit in every patient |
| Class IIa | Reasonable/should be considered | Treated as mandate |
| Class IIb | May be considered | Presented as established care |
| Level A | Multiple RCTs/meta-analysis | Assumed current and universally generalizable |
| Level B | One RCT or nonrandomized evidence, depending system | Conflated across grading systems |
| Level C | Limited data/expert opinion | Hidden behind strong prose |
Guideline grades are not directly interchangeable between organizations. Always inspect the population, comparator, outcome, absolute effect, and evidence date.
Gaps across all guidelines¶
- Advanced CKD, frailty, multimorbidity, pregnancy, and very old adults remain underrepresented in trials.
- INOCA treatment recommendations rely heavily on mechanistic and symptom evidence rather than hard outcomes (Kunadian 2020, PMID 32626906).
- Live PubMed and ClinicalTrials.gov searches repeated on 2026-09-02 still found no completed validated hsCRP-targeted anti-inflammatory strategy. RIGHT registered hsCRP-enriched colchicine randomization, but its status is unknown and no results are posted (Jolly 2025, PMID 39555823; NCT06025071).
- Lp(a)HORIZON completed in July 2026, but no primary outcome publication was found in PubMed searches repeated on 2026-09-02 (the trial's most recent indexed output is an Lp(a) unit-concordance analysis, Cho 2026, PMID 42250319); OCEAN(a)-Outcomes remains active without recruitment (NCT04023552; NCT05581303).
- Implementation recommendations lack the evidence density of drug and device sections despite large treatment gaps.
Recommendation reconciliation workflow¶
| Step | Output |
|---|---|
| Identify issuing body and evidence cutoff | Prevents mixing publication year with search year |
| Match patient to scope | Chronic, ACS, revascularization, lipid, or prevention |
| Extract class/strength and evidence level | Separates recommendation from evidence certainty |
| Recover underlying absolute effect | Makes benefit interpretable |
| Record exclusions and contraindications | Preserves trial transportability |
| Compare regulatory/access assumptions | Explains regional divergence |
| Check supersession chain | Avoids applying obsolete recommendations |
| Document patient preference/resource constraint | Converts guidance into a transparent decision |
When two guidelines differ, this workflow usually reveals a difference in scope, cutoff, grading system, or health-system assumption before a true disagreement in evidence (Virani 2023, PMID 37471501; Vrints 2024, PMID 39210710).
Where evidence permits more than one defensible recommendation¶
| Controversy | Evidence that narrows the question | Why recommendations still differ |
|---|---|---|
| Routine invasive care in stable CAD | ISCHEMIA found no reduction in net death or total MI over median 3.2 years (Maron 2020, PMID 32227755); extended follow-up showed lower CV but higher non-CV mortality without all-cause survival benefit (Hochman 2023, PMID 36335918). | Guidelines weight symptom burden, spontaneous versus procedural MI, anatomy, life expectancy, and patient preference differently. |
| PCI for symptoms | ORBITA did not significantly improve exercise-time increment after medication optimization, whereas ORBITA-2 improved daily angina score off background antianginals (Al-Lamee 2018, PMID 29103656; Rajkumar 2023, PMID 38015442). | Different medication states and endpoints make both trials true without making them interchangeable. |
| Left-main PCI versus CABG | Long-term trial and pooled analyses show similar mortality in selected low-complexity left-main anatomy but different spontaneous MI and repeat-revascularization profiles (Sabatine 2021, PMID 34793745; Byrne 2023, PMID 37632766). | Procedural-MI definitions, anatomic complexity, surgical durability, and local expertise change the preferred strategy. |
| Diabetes with multivessel disease | Pooled randomized evidence favors CABG survival in diabetes/multivessel disease (Head 2018, PMID 29478841), with only small intermediate health-status differences in FREEDOM (Abdallah 2013, PMID 24129463). | Operative risk, frailty, graft targets, recovery burden, and patient priorities can outweigh the population average. |
| Ischemic LV dysfunction | STICHES supports long-term CABG plus medical therapy, while REVIVED found no death/HF-hospitalization benefit from PCI (Velazquez 2016, PMID 27040723; Perera 2022, PMID 36027563). | Route, completeness, anatomy, surgical candidacy, and treatment era prevent treating CABG and PCI as one “revascularization” class. |
| Post-MI beta-blocker duration | REDUCE-AMI was neutral with preserved EF; ABYSS did not establish interruption as noninferior (Yndigegn 2024, PMID 38587241; Silvain 2024, PMID 39213187). | “No need to start routinely” and “safe to stop” are different causal questions. |
| Colchicine | COLCOT and LoDoCo2 were positive, but CLEAR SYNERGY was neutral after acute MI (Tardif 2019, PMID 31733140; Nidorf 2020, PMID 32865380; Jolly 2025, PMID 39555823). | Timing, adherence, background treatment, endpoint mix, and non-CV safety remain unresolved. |
| LDL escalation | US chronic-CAD guidance uses maximally tolerated therapy and thresholds; ESC documents use explicit goals plus ≥50% reduction (Virani 2023, PMID 37471501; Vrints 2024, PMID 39210710; Mach 2025, PMID 40885687). | The evidence shows a continuous LDL effect; goals versus thresholds are implementation choices layered onto cost and access. |
| INOCA function testing | CorMicA improved symptoms with endotype-linked therapy, and reduced CFR predicts events (Ford 2018, PMID 30266608; Kelshiker 2022, PMID 34849697). | Hard-outcome strategy evidence and widespread testing capacity remain limited. |
A transparent reconciliation rule¶
When recommendations conflict, record five items: exact population, comparator, endpoint and time horizon, evidence certainty, and resource assumptions. US revascularization guidance, the joint ESC/EACTS left-main review, and ESC chronic-coronary guidance can then be compared at the level of the same clinical question rather than their headline class labels (Writing Committee 2022, PMID 34895950; Byrne 2023, PMID 37632766; Vrints 2024, PMID 39210710). Acute guidance requires the same treatment: ESC 2023 and ACC/AHA 2025 agree more than they differ once shock, bleeding risk, radial access, and nonculprit anatomy are specified (Byrne 2023, PMID 37622654; Rao 2025, PMID 40014670).
Recommendations also embed a health-system model. CCTA-first pathways, invasive coronary-function testing, PCSK9 therapy, and rapid PCI networks assume different capacity from essential-medicine and total-risk programs. Guideline discordance is therefore sometimes an access disagreement rather than an evidence disagreement (Visseren 2021, PMID 34458905; Gulati 2021, PMID 34709879).
Exact recommendation grades expose real disagreements¶
The joint ESC/EACTS reassessment makes the left-main controversy explicit rather than calling the procedures equivalent. For stable left-main disease with low/intermediate SYNTAX score, anatomy suitable for either route, and low predicted surgical mortality, CABG retained Class I, Level A while PCI was assigned Class IIa, Level A; the panel emphasized that four aggregated trials could exclude only large mortality differences (Byrne 2023, PMID 37632756). Same evidence level therefore does not mean same recommendation strength.
Cardiac rehabilitation shows the inverse problem: a strong recommendation with weak delivery. The Million Hearts roadmap describes post-MI/revascularization CR as Class I, Level A, yet US participation was only 20%–30%; its modeled target of 70% participation projected 25,000 deaths and 180,000 hospitalizations avoided annually, estimates that depend on successfully transporting efficacy into uptake (Ades 2017, PMID 27855953). In 30,191 Swedish 1-year MI survivors, the highest versus lowest income quintile had odds ratios of 2.28 (95% CI 2.11–2.46) for physical-training participation and 2.29 (95% CI 2.12–2.47) for education despite publicly financed care (Ohm 2021, PMID 33688966).
DAPT illustrates an evidence-lineage dispute. A contemporary review notes that 12-month ACS DAPT remains the only Class I duration recommendation in US and European guidance, although CURE compared DAPT with no DAPT and averaged 9 months rather than randomizing 12 versus shorter duration; later trials support shortening for bleeding risk and extension for selected ischemic risk (Valgimigli 2024, PMID 39038086). Guideline tables should therefore record the causal comparison underlying each class, not only its label.
Open questions¶
- Can international guideline groups harmonize LDL language without concealing cost and access constraints?
- How should CLEAR SYNERGY alter colchicine recommendations written after COLCOT/LoDoCo2? (Jolly 2025, PMID 39555823)
- Will 2025 ACS guidance improve uptake of complete revascularization, rehabilitation, and lipid intensification in practice? (Rao 2025, PMID 40014670)
- Which revascularization recommendations will change after STICH3C and longer PREVENT follow-up?
- Can guideline adherence be measured as patient-level care bundles rather than isolated prescriptions?
Related pages¶
- Stable CAD management — trials underlying chronic recommendations.
- Acute coronary syndromes — acute pathways.
- Revascularization: PCI and CABG — anatomy-specific evidence.
- Lipid lowering — target and threshold evidence.
References¶
- Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119. PMID 37471501
- Vrints C, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415-3537. PMID 39210710
- Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-3826. PMID 37622654
- Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e771-e862. PMID 40014670
- Writing Committee Members, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21-e129. PMID 34895950
- Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144:e368-e454. PMID 34709879
- Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337. PMID 34458905
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188. PMID 31504418
- Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 2025;409:120479. PMID 40885687
- Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395-1407. PMID 32227755
- Byrne RA, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur J Cardiothorac Surg. 2023;64:ezad286. PMID 37632766
- Kunadian V, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41:3504-3520. PMID 32626906
- Jolly SS, et al. Colchicine in Acute Myocardial Infarction. N Engl J Med. 2025;392:633-642. PMID 39555823
- Hochman JS, et al. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023;147:8-19. PMID 36335918
- Al-Lamee R, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31-40. PMID 29103656
- Rajkumar CA, et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N Engl J Med. 2023;389:2319-2330. PMID 38015442
- Sabatine MS, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398:2247-2257. PMID 34793745
- Head SJ, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391:939-948. PMID 29478841
- Abdallah MS, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA. 2013;310:1581-90. PMID 24129463
- Velazquez EJ, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374:1511-20. PMID 27040723
- Perera D, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022;387:1351-1360. PMID 36027563
- Yndigegn T, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390:1372-1381. PMID 38587241
- Silvain J, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024;391:1277-1286. PMID 39213187
- Tardif JC, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497-2505. PMID 31733140
- Nidorf SM, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383:1838-1847. PMID 32865380
- Ford TJ, et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018;72:2841-2855. PMID 30266608
- Kelshiker MA, et al. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J. 2022;43:1582-1593. PMID 34849697
- Byrne RA, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur Heart J. 2023;44:4310-4320. PMID 37632756
- Ades PA, et al. Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative. Mayo Clin Proc. 2017;92:234-242. PMID 27855953
- Ohm J, et al. Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After Myocardial Infarction. JAMA Netw Open. 2021;4:e211129. PMID 33688966
- Valgimigli M, et al. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024;150:317-335. PMID 39038086
- Cho L, et al. Concordance of Lipoprotein(a) measurements in mg/dL and nmol/L: Insights from the Lp(a)HORIZON trial. Atherosclerosis. 2026;418:120796. PMID 42250319